Search
Semaglutide
go.drugbank.com/drugs/DB13928ApprovedInvestigationalSemaglutide was developed by Novo Nordisk and approved by the FDA for subcutaneous injection in December 2017.[L8681] The tablet formulation was approved for oral administration in September 2019. … [A186053] In June 2021, semaglutide was approved by the FDA for chronic weight management in adults with general obesity or overweight who have at least one weight-related condition, marking semaglutide
Categories: Drugs Used in DiabetesProducts: OZEMPIC 1MG/DOSE SOLUTION FOR INJECTION IN PRE-FILLED PEN 1.34MG/ML, OZEMPIC 0.25MG, 0.5MG/DOSE SOLUTION FOR INJECTION IN PRE-FILLED PEN 1.34MG/MLGlatiramer
go.drugbank.com/drugs/DB05259ApprovedInvestigational[A248870] Along with [human interferon beta], [teriflunomide], and [dimethyl fumarate], glatiramer acetate is a first-line drug for patients with MS. … [A248880] It was approved by the FDA in 1996, and a generic version became available in 2017.
Products: Copaxone 20 mg/ml Injektionslösung in einer Fertigspritze, Copaxone 40 mg/ml Injektionslösung in einer FertigspritzeTirzepatide
go.drugbank.com/drugs/DB15171ApprovedInvestigational[L48766] On September 15, 2022, tirzepatide was also approved by the European Commission.[L44386]. On November 02, 2023, tirzepatide was also approved by the Health Canada [L52800] … [A246260] Its protein sequence was based on the sequence of endogenous GIP, and its pharmacological action on GLP-1 receptors is comparable to endogenous GIP; however, the long half-life of tirzepatide
Categories: Drugs Used in DiabetesProducts: Mounjaro 2.5 mg solution for injection in pre-filled pen, Mounjaro 5 mg solution for injection in pre-filled penSotatercept
go.drugbank.com/drugs/DB12118ApprovedInvestigational[L50351] On March 26, 2024, sotatercept was approved by the FDA for the treatment of pulmonary arterial hypertension (PAH). … [L50361] Sotatercept works to resolve the imbalance in activin–growth differentiation factor and BMP pathway signalling observed in PAH.
Miconazole
go.drugbank.com/drugs/DB01110ApprovedVet approved[A203636, A203639] Miconazole was first synthesized in 1969 and first granted FDA approval on January 8, 1974, for sale by INSIGHT Pharmaceuticals as a topical cream. … Despite having been in clinical use for an extended period, resistance to miconazole among susceptible organisms is relatively low.[A203636]
Mixtures: Monistat 3 Dual-pak, Monistat 3 Dual-pakProducts: Welmedix HomeCare PRO 2-in-1 Antifungal and Skin ProtectantPeanut oil
go.drugbank.com/drugs/DB13964ApprovedWithdrawn[A33169] Under the FDA, peanut oil is categorized as an approved inactive ingredient for its use in drug products. … [L2242] Under Health Canada, it is approved as an active ingredient in over-the-counter combination products.[L1113]
Metamizole
go.drugbank.com/drugs/DB04817ApprovedInvestigationalWithdrawn[L42975] In 1963, metamizole was withdrawn from the Canadian market and banned in the UK, France, Sweden, Norway and Australia. … [A251885] Metamizole was formerly marketed in the US as Dimethone tablets and injection, Protemp oral liquid, and other drug products, and was withdrawn due to its association with potentially fatal agranulocytosis
Mixtures: BIPASMIN COMPUESTO N, BIPASMIN COMPUESTO NNivolumab
go.drugbank.com/drugs/DB09035ApprovedInvestigational[A35203] It was developed by Bristol Myers Squibb.[L12129] Nivolumab was granted FDA approval on 22 December 2014. … [L12129] This antibody was produced entirely in mice and grafted onto human kappa and IgG4 Fc region with the mutation _S228P_ for additional stability and reduced variability.
Iophendylate
go.drugbank.com/drugs/DB01187ApprovedIophendylate, which was never shown to be safe, was initially introduced for use in small amounts (1-2cc) for locating spinal tumors. … In 1942 Van Wagenen (a neurosurgical colleague of Warrens, at the University of Rochester) identified Iophendylate as causing chemical meningitis in 30 patients where "space-displacing masses within the
Categories: Compounds used in a research, industrial, or household settingEdaravone
go.drugbank.com/drugs/DB12243ApprovedInvestigational[L44017] Edaravone was initially granted orphan designation by the European Medicines Agency on June 19, 2015 [L44007] and was under regulatory review in Europe. … [L44007] The oral suspension formulation of edaravone was approved by the FDA in May 2022 and by Health Canada in November 2022.
Categories: Compounds used in a research, industrial, or household setting